Dr. Julie Rudnicki is Vice President, Global Androgen Receptor Degrader Assets Program Leader at Arvinas. Dr. Rudnicki has over 25 years of experience and leadership in the pharmaceutical and biotechnology industry ranging from research through late-stage drug development and life cycle management.
Dr. Rudnicki joins Arvinas after serving as Vice President, Global Program and Alliance Management at Zentalis Pharmaceuticals, where she established the Program and Alliance department and was responsible for development of long-term integrated asset strategies and management of alliance partnerships for the clinical-stage oncology portfolio.
Previously, Dr. Rudnicki served as Head of Global Program Management at Ichnos Sciences, where she was responsible for life cycle strategy and operational planning for the autoimmune, oncology and pain programs while supporting business development efforts. Prior to this, Dr. Rudnicki was Global Program Leader for the Nexavar® program and subsequently Head of Global Clinical Development Process Excellence at Bayer Healthcare Pharmaceuticals.
Dr. Rudnicki started her career at Boehringer Ingelheim Pharmaceuticals as a postdoctoral fellow and held leadership roles of increasing responsibility in the areas of international program management and alliance management. She received her Ph.D. in Cell Biology and Genetics from Cornell University and her B.S. in Biology from William Smith College.
